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To the Editor,
We thank you and the reviewers for considering our initial manuscript, Ms. No.: NOX-2016-120 
entitled “Influence of iodide ingestion on nitrate metabolism and blood pressure following short-
term dietary nitrate supplementation in healthy normotensive adults”, for publication in Nitric 
Oxide.  Please find enclosed our revised manuscript entitled “Influence of iodide ingestion on 
nitrate metabolism and blood pressure following short-term dietary nitrate supplementation in 
healthy normotensive adults” for consideration by Nitric Oxide.  We thank the editor for allowing 
us to submit a revised manuscript to be considered for publication in Nitric Oxide. We are grateful 
to the reviewers for their detailed reports and have responded to each of their comments in the 
“response to reviewers” document.  The manuscript has been adjusted as required.  Through the 
process of addressing the reviewers’ comments, we feel the manuscript is much improved and hope 
that you deem it of a standard acceptable for publication in Nitric Oxide.
Yours sincerely,
Stephen J. Bailey PhD
Ms. No.: NOX-2016-120 entitled “Influence of iodide ingestion on nitrate metabolism and 
blood pressure following short-term dietary nitrate supplementation in healthy 
normotensive adults”
Comment to the Editor:  We thank the editor for allowing us to submit a revised 
manuscript to be considered for publication in Nitric Oxide. We are grateful to the 
reviewers for their detailed reports and have responded to each of their comments 
below.  The manuscript has been adjusted as required.  Through the process of 
addressing the reviewers’ comments, we feel the manuscript is much improved and 
hope that you deem it of a standard acceptable for publication in Nitric Oxide.
-Reviewer 1
  - Bailey and colleagues investigated whether dietary iodide intake altered handling, 
metabolism and clinical effect on blood pressure of concomitant dietary nitrate ingestion in 9 
healthy volunteers
They demonstrated small effects from supra-ADI iodide intake on plasma nitrate but not 
nitrite levels, and no effects on blood pressure, suggesting that nitrate uptake/secretion by 
salivary glands is not rate limiting.
The manuscript is well presented and referenced
Thank you for your thorough review of the manuscript and the positive comment.
Minor comments:
1. The authors should distinguish processes that occur in salivary glands [nitrate uptake] from 
saliva [perhaps some nitrate reduction and carriage of nitrite to stomach] to make it easier for 
non-experts to understand the processes referred to in this manuscript
We have added text in the introduction to distinguish between processes that occur in 
the salivary glands from the role that saliva plays in dietary nitrate metabolism, as 
requested.
2. I think the conclusions of this manuscript could be altered to say that at these doses 
investigated, iodide competition reveals that salivary gland processes are not rate limiting for 
the physiological effects of nitrate supplementation at doses studied
The conclusion has been amended to more clearly indicate that the supra-ADI dose of 
iodide administered in this study is unlikely to interfere with the increases in salivary 
and plasma [nitrite] and the lowering of blood pressure after dietary nitrate 
supplementation.  However, while our findings in this study suggest that the salivary 
glands might not be limiting for dietary nitrate metabolism and some of its vascular 
benefits, our recent study (Bailey et al., 2016, Nitric Oxide) showed that when plasma 
and salivary [thiocyanate] [a more potent competitive inhibitor of salivary nitrate 
uptake (Edwards et al., 1954, Lancet)] is greater, as occurs in cigarette smokers, 
salivary [nitrate] and plasma [nitrite] increase less and the lowering of blood pressure is 
attenuated after nitrate supplementation in smokers compared to non-smoking 
controls.  Therefore, the uptake of nitrate into the salivary gland can rate-limit dietary 
nitrate metabolism.  As a result, we cannot state that salivary glands are not rate-
limiting to dietary nitrate metabolism on the balance of the existing evidence on the 
topic.   
3. Why were different molar amounts of KI and K-gluconate used [300-fold difference 
between treatments] ? This should be explained and commented on in a limitation section. 
Could there be contamination of BP results as one treatment had more K supplementation 
that may lower BP in short term intervention studies [see any number of McGregor and He 
reviews]
This is a good point and we have acknowledged this as a potential limitation in the 
revised discussion.  These doses were selected based on the supplements the company 
was able to provide.  However, while we concede that inter-trial differences in 
potassium ingestion might have impacted the blood pressure responses somewhat, a 
recent Cochrane review concluded that potassium supplementation does not alter blood 
pressure in primary hypertensives (Dickinson et al., 2006) with additional evidence that 
potassium supplementation does not impact blood pressure in normotensive adults (e.g., 
Barden et al., 1986, Hypertension; Miller et al., 1987, Hypertension).  Therefore, based 
on this evidence, we are confident that the differences in potassium content between the 
nitrate and nitrate + iodide trials would not have impacted our conclusion that blood 
pressure was not different between these two experimental conditions.     
What is the half life of KI and K-gluconate? is a 7 day washout adequate? How is gluconate 
handled by the body, could itself impact on gastric/salivary handling of NOx species?
We are not aware of any evidence to suggest that gluconate could impact any of the key 
processes responsible for the stepwise reduction of nitrate to nitrite and then nitric 
oxide, which was why it was selected as a placebo in the current study.  The half-life for 
iodide has been reported as ~ 8 hours (Delgado et al., 2015, Thyroid).  Therefore, the 7 
day washout should have been sufficient for plasma [iodide] to return to baseline 
between conditions.   
4.  Why did the protocol have double supplementation on the final morning? lack of steady 
state kinetics would abound perhaps and should be commented on in a limitation section
The total daily supplementation dose was consumed 2 hours prior to testing to coincide 
with the peak plasma [NO2-] attained following ingestion of 8.4 mmol NO3- (Wylie et al., 
2013, JAP).  We have acknowledged in the revised discussion that is it unclear if these 
results would be reproduced on days 1-5 of supplementation when the plasma and 
salivary [nitrate] and [nitrite] pharmacokinetics were likely different.
5. What were the basal nitrate levels in CON in plasma as only change from baseline is 
showed in figure 3. Is 40uM plasma nitrate difference physiologically relevant. Based on the 
known conversion of plasma nitrite via ES circulation to plasma nitrite being on a few %, 
perhaps not at all surprising that no diff in plasma nitrite noted. This should be commented 
on.
The revised results section provides plasma [nitrate] in the control trial as requested.  
Based on our previous dose-response study (Wylie et al., 2013, JAP), the difference in 
plasma [nitrate] between the nitrate and nitrate + iodide trials, although statistically 
significant, did not meaningfully impact the changes in plasma [nitrite] and blood 
pressure in this study.  We have added text in the discussion section to make this clear.
6. What was the sample size based on. A priori power calculations should be shown.
The effect of nitrate and iodide co-ingestion was not known so it was not possible to 
provide a direct power calculation. The sample size was based on the effect size for the 
change in plasma [nitrite] in smokers, who had a higher plasma [thiocyanate] (another 
competitive inhibitor of salivary nitrate uptake) than non-smokers, after the same 
dietary nitrate supplementation procedures as used in this study.  The effect size for the 
increase in plasma [nitrite] after dietary nitrate supplementation in smokers was 1.7.  
For a high statistical power (0.80) with an alpha error probability of 0.05, a sample of 5 
would be required to detect this effect.  Although the sample was small in this study, the 
effect size for the change in plasma [nitrite] from the nitrate and nitrate + iodide 
conditions was -0.03.  Therefore, a larger sample would not influence the conclusions of 
our study.
-Reviewer 2
  - 
The paper by Stephen Bailey and co-authors tested the hypothesis that I- ingestion would 
interfere with nitrate- metabolism and blunt blood pressure reductions after dietary nitrate - 
supplementation. In a small randomized, cross-over trial, nine healthy adults were enrolled. 
After an initial baseline assessment (CON), the volunteers received six-day supplementation 
with NO3-rich beetroot juice (8.4 mmol NO3/day) plus 198 mg potassium gluconate (NIT) or 
NO3-rich beetroot juice and 450 μg potassium iodide/day (NIT + I). In summary: 
a)       Salivary [I-] was higher in NIT + I compared to CON and NIT. 
b)      Salivary and plasma [NO3-] and [NO2-] were higher in NIT and NIT + I compared to 
CON
c)       Plasma [NO3-] was higher (474 ± 127 vs. 438 ± 117 µM) and the salivary-plasma 
[NO3-] ratio was lower (14 ± 6 vs. 20 ± 6 µM) in NIT + I compared to NIT (P<0.05), 
suggesting of a lower salivary NO3- uptake.
d)      Plasma and salivary [NO2-] were not different between NIT and NIT + I (P>0.05). 
e)      Compared to control, Systolic blood pressure and MAP were lower in NIT and in 
NIT + I arm with no differences between them (P>0.05).
Based in their results, the authors argue that increased dietary I- intake, which is 
recommended in several countries to prevent iodine deficiency, does not compromise the 
blood pressure-lowering effect of dietary nitrate.
 
Positive points 
 - The paper is well written in overall, the figures are ok, legends are adequate, and the 
statistic is adequate.
- This is an interesting study and potentially important in a growing field
Thank you for your thorough review of the manuscript and the positive comments. 
However, while the topic is quite interesting, there is no clear explanations why authors 
would expect major differences induced by the chosen dose of Iodine. The nitrate plasma 
concentration is quite high (40-60 micro molar) compared to iodide plasma concentration 
reported in the literature.
This is a good point.  Plasma [iodide] is lower than plasma [nitrate] based on the 
literature.  There is evidence to suggest that competitive inhibition of the thyroid gland 
anion transporter is ~ 8 times greater for iodide compared to nitrate (Tonacchera et al., 
2004, Thyroid).  However, while iodide has been shown to competitively inhibit nitrate 
uptake into the salivary gland (Edwards et al., 1954, Lancet) the magnitude of this effect 
is not clear.  We have included this additional information to provide a more clear 
rationale for the current study in line with your suggestion.  
It makes complicate to explain an interesting increase in plasma nitrate in described in Figure 
3A for NIT + I group, which suggest that in some way Iodide supplementation is interfering 
with nitrate bioavailability. And; still, the lower salivary I- reported in NIT group (Fig 1) – 
Would be nitrate supplementation interfering in iodine transportation? 
This is an interesting point.  Perchlorate, thiocyanate, iodide and nitrate compete for 
transport into the salivary glands such that increasing iodide intake would be 
hypothesised to lower salivary nitrate uptake at a given nitrate dose, which is confirmed 
by our finding of a higher plasma [nitrate] and a lower salivary-plasma [nitrate] ratio 
with concurrent nitrate and iodide supplementation compared to nitrate 
supplementation alone.  On the other hand, increasing nitrate intake would be 
hypothesised to lower salivary iodide uptake at a given iodide dose, which is confirmed 
by our finding of a lower salivary [iodide] after nitrate supplementation with no iodide 
supplementation compared to the control trial with no iodide or nitrate 
supplementation.  This concept is covered in the second paragraph of our discussion.   
 
Major points
- The missing CON + I arm (control + iodide supplementation) does not invalidate their 
findings but it would greatly   improve the MS
We agree that this additional experimental arm would improve the inferences that can 
be drawn from our data.  Unfortunately, it is not possible to complete these additional 
experiments since too much time has elapsed since the original experiments were 
conducted and the participants are no longer students at the University of Exeter.  
However, since the purpose of this study was to assess the impact of iodide ingestion on 
dietary nitrate metabolism and blood pressure after nitrate supplementation, rather 
than the effects of iodide ingestion on basal dietary nitrate metabolism and blood 
pressure, we feel our study provides sufficient data to address the experimental 
hypotheses.  Nonetheless, we have conceded in the revised discussion that the effects of 
iodide ingestion on basal dietary nitrate metabolism and blood pressure were not 
assessed in this study which is an area for further research.  
- The abstract should be improved; the paper is much better that the abstract report
We have made some improvements to the abstract as requested.
- The authors must report the absolute values, for all groups, including the control group. The 
delta values reported makes complicated to evaluate the baseline conditions.
Absolute values for all data are now either stated in the results section or presented in 
Tables 1-2.  
- Could the authors explain why potassium gluconate was used as placebo? In addition, the 
abstract reports 198 mg potassium gluconate (NIT) and the methods section 99 mg potassium 
gluconate. Which dose was used?
The daily potassium gluconate dose was 198 mg.  On days 1-5 of supplementation, 
subjects consumed 1 x 99 mg potassium gluconate capsule in the morning and evening, 
whereas on day 6 of supplementation, subjects consumed 2 x 99 mg potassium gluconate 
capsules 2 hours prior to testing.  This section has been rewritten and a figure of the 
experimental protocol (figure 1) has been provided to improve clarity. 
- In the methods section, maybe would be better to improve the description of experimental 
protocol used, maybe a figure would make it simple and didactical.
We agree and have provided a figure (Figure 1) to illustrate the experimental protocol 
employed more clearly.
- Discussion section, page 10, line 6: rephrase this paragraph or add a suitable reference  
This sentence has been deleted and we have rephrased this paragraph as requested.
 
 
Minor points
 
-          Maybe would be interesting to the authors read a recent paper in hypertension (PMID: 
27802417) and update the discussion in 5th paragraph, page 10, as well another one that 
evaluate the differences in plasma/saliva nitrate/nitrite ratios (PMID: 27810735) after a 
dietary dose of nitrate
Thank you for pointing out these excellent recent papers.  We were not able to reference 
these in our original submission as they had not been published.  These have been 
referenced in our revised discussion section.  
-          Maybe would be interesting to the authors report the regular name “Nitrate” instead “NIT”, 
Control instead CON, and Nitrate + I instead “NIT + I”. The “NIT” is quite simple to be 
confounded by nitrite  
This has been changed in line with your suggestion.
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2ABSTRACT
Uptake of inorganic nitrate (NO3-) into the salivary circulation is a rate-limiting step for 
dietary NO3- metabolism in mammals.  It has been suggested that salivary NO3- uptake occurs 
in competition with inorganic iodide (I-).  Therefore, this study tested the hypothesis that I- 
supplementation would interfere with NO3- metabolism and blunt blood pressure reductions 
after dietary NO3- supplementation.  Nine healthy adults (4 male, mean ± SD, age 20 ± 1 yr) 
reported to the laboratory for initial baseline assessment (CON control) and following six day 
supplementation periods with 140 ml·day-1 NO3--rich beetroot juice (8.4 mmol NO3-·day-1) 
and 198 mg potassium gluconate·day-1 (NIT nitrate), and 140 ml·day-1 NO3--rich beetroot 
juice and 450 μg potassium iodide·day-1 (NIT + I nitrate + iodide) in a randomized, cross-
over experiment.  Salivary [I-] was higher in the NIT + I nitrate + iodide compared to CON 
the control and NIT trials (P<0.05).  Salivary and plasma [NO3-] and [NO2-] were higher in 
NIT the nitrate and NIT + I nitrate + iodide trials compared to CON the control trial 
(P<0.05).  Plasma [NO3-] was higher (474 ± 127 vs. 438 ± 117 µM) and the salivary-plasma 
[NO3-] ratio was lower (14 ± 6 vs. 20 ± 6 µM), indicative of a lower salivary NO3- uptake, in 
the NIT + I nitrate + iodide trial compared to NIT the nitrate trial (P<0.05), indicative of a 
lower salivary NO3- uptake.  Plasma and salivary [NO2-] were not different between NIT the 
nitrate and NIT + I nitrate + iodide trials (P>0.05).  Systolic blood pressure was lower than 
CON control (112 ± 13 mmHg) in NIT the nitrate (106 ± 13 mmHg) and NIT + I nitrate + 
iodide (106 ± 11 mmHg) trials (P<0.05), with no differences between NIT the nitrate and 
NIT + I nitrate + iodide trials (P>0.05).  In conclusion, co-ingesting NO3- and I- perturbed 
salivary NO3- uptake, but the increase in salivary and plasma [NO2-] and the lowering of 
blood pressure were similar, compared to NO3- ingestion alone.  Therefore, increased dietary 
I- intake, which is recommended in several countries worldwide as an initiative to offset 
hypothyroidism, does not appear to compromise the blood pressure reduction afforded by 
increased dietary NO3- intake.    
Key Words: Entero-salivary circulation; nitrite; nitric oxide; vascular health; nutrition 
31. INTRODUCTION
The gaseous molecule, nitric oxide (NO), regulates an array of physiological processes, but is 
perhaps best known for its vasodilatory and cardioprotective properties [1,2].  It has been 
demonstrated that NO can be generated through the O2-independent reduction of nitrite (NO2-
) to complement O2-dependent NO generation through the NO synthases [3-5].  The 
circulating plasma [NO2-] can be increased through dietary supplementation with inorganic 
nitrate (NO3-) and is associated with a reduction in blood pressure and arterial stiffness [6-8], 
important predictors of future adverse cardiovascular events [9,10].  In addition, NO3- 
supplementation can improve vascular function in healthy older adults [11] and some clinical 
populations including patients with peripheral artery disease [12] and heart failure [13].  
Increasing dietary NO3- intake, therefore, appears to confer cardioprotective effects and might 
hold promise as a nutritional intervention to lower the societal and economic burden of 
cardiovascular diseases [14]. 
Approximately 25% of NO3- consumed through the diet is actively taken up and concentrated 
by the salivary glands [15].  NO3- is then transported in saliva to the mouth for second-pass 
metabolism via the so-called entero-salivary circulation [15-19].  passes into the entero-
salivary circulation where it is delivered to the mouth for second-pass metabolism [15].  
Upon arrival of NO3--rich saliva at the oral cavity, microflora on the tongue reduce NO3- to 
NO2- [15-19].  After swallowing this NO2--rich saliva, NO2- is chemically reduced to NO and 
other reactive nitrogen intermediates in the acidic environment of the stomach [20,21], but it 
is well documented that the circulating plasma [NO2-] is also increased after increased NO3- 
intake [6-8,18].  This circulating plasma NO2- can then impact vascular function either 
through direct NO2- action [22,23] or through its subsequent reduction to NO via numerous 
NO2- reductases [24].  While mammalian tissue is capable of reducing NO3- to NO2- [25], the 
rate limiting steps for NO3- reduction in mammals are NO3- transport into the entero-salivary 
circulation and NO3- reduction to NO2- by the oral microflora [26].  Importantly, the anions 
perchlorate (CIO4-), thiocyanate (SCN-), iodide (I-) and NO3- share a common transporter for 
uptake into the salivary glands, with the order of affinity for salivary uptake being CIO4- > 
SCN- > I- > NO3- [27].  Although CIO4- has the highest affinity for salivary uptake of the 
aforementioned anions [27], environmental exposure to CIO4- is limited [28,29].  
Consequently, the competition between SCN-, I- and NO3- is more likely to be pertinent for 
4NO3- transfer into the entero-salivary circulation [28,29] and, subsequently, the stepwise 
reduction of NO3- to NO2- and then NO. 
It has recently been reported that cigarette smoking [30], which increased salivary and plasma 
[SCN-], perturbed aspects of dietary NO3- metabolism, and thwarted the lowering of blood 
pressure, after dietary NO3- supplementation.  There is evidence to suggest that compared to 
nitrate iodide is ~ 8 times more effective at competitively inhibiting the anion transporter in 
the human thyroid gland [31].  Although I- has previously been suggested to interfere with 
salivary NO3- uptake [27], the relative potency of I- to inhibit salivary NO3- uptake has yet to 
be determined.  As such, it is unclear whether increasing the circulating [I-] via I- 
supplementation can compromise salivary NO3- uptake after NO3- ingestion.  However, it is 
also possible that any potential perturbation to salivary NO3- uptake after NO3- and I- co-
ingestion might be offset by a compensatory increase in NO generation in the stomach.  
Indeed, nitrous acid (HNO2), which is formed from the protonation of ingested salivary NO2- 
in the stomach [32], can react with I- to form NO at an acidic pH [33].  Accordingly, further 
research is required to assess the extent to which dietary I- enrichment impacts dietary NO3- 
metabolism and associated vascular health benefits after dietary NO3- supplementation.  This 
is important because I- is present in numerous food sources, with seafood and dairy products, 
particularly seaweed, white fish, yogurt and milk, being abundant in I- [34].  Moreover, in 
excess of 100 countries fortify their salt with I-, or mandate the use of iodised salt for the 
production of products such as bread, in an effort to alleviate the prevalence of 
hypothyroidism [35,36].  These government initiatives have been successful at increasing I- 
exposure [36], but it is unclear if this might be to the detriment of dietary NO3- metabolism.     
The purpose of this study was to examine the effect of co-supplementation with NO3- and I-, 
compared to NO3- supplementation alone, on dietary NO3- metabolism and blood pressure.  
We hypothesised that NO3- supplementation would increase salivary and plasma [NO3-] and 
[NO2-] and lower blood pressure, but that concurrent NO3- and I- supplementation would 
attenuate: 1) salivary NO3- uptake, 2) the increase in circulating plasma [NO2-] and 3) the 
lowering of blood pressure compared to NO3- supplementation alone.     
52. METHODS
2.1 Subject characteristics
We recruited nine healthy non-smoking adults (4 males, mean ± SD, age 20 ± 1 yr, body 
mass 71 ± 16 kg, height 1.72 ± 0.11 m) to participate in this study.  All procedures employed 
in this study were approved by the Institutional Research Ethics Committee and subjects gave 
their written informed consent to participate after the experimental procedures, associated 
risks, and potential benefits of participation had been explained.  Subjects were instructed to 
arrive at each laboratory testing session in a rested and fully hydrated state, at least 3 h 
postprandial.  Since the reduction of NO3- to NO2- in the oral cavity is abolished by 
antibacterial mouthwash [37,38], subjects were required to refrain from mouthwash use for 
the duration of the study.  Each subject was given a list of NO3--rich and SCN--rich foods and 
asked to avoid consumption of these foods for the duration of the study, and to abstain from 
caffeine and alcohol ingestion 6 and 24 h before each test, respectively.  Subjects were 
instructed to maintain their habitual exercise pattern for the duration of the study.   All tests 
were performed at the same time of day (± 2 hours).   
2.2 Supplementation Procedures
All subjects were required to report to the laboratory on three occasions over a 3-4 week 
period.  Subjects did not undergo dietary supplementation prior to their first visit to the 
laboratory (the control condition; CON).  Subjects were asked to record their food and 
beverage consumption on the day of the CON control test and for the 2 days preceding this 
test and to replicate this prior to the subsequent trials.  After completing the CON control 
trial, subjects were randomly assigned to receive six days of supplementation with 2 × 70 ml 
NO3--rich beetroot juice (8.4 mmol NO3-) and 2 × 99 mg potassium gluconate placebo 
capsules (NIT nitrate), or 2 × 70 ml NO3--rich beetroot juice and 2 × 225 μg potassium iodide 
capsules (NIT + I nitrate + iodide), per day as part of a double-blind, cross-over experimental 
design (Figure 1).  Subjects consumed 1 × 70 ml NO3--rich beetroot juice and 1 × 99 mg 
potassium gluconate placebo capsule (NIT nitrate) or 1 × 225 μg potassium iodide capsule 
(NIT + I nitrate + iodide) in the morning and evening on days 1-5 of supplementation and 2 × 
70 ml NO3--rich beetroot juice with 2 × 99 mg potassium gluconate placebo capsules (NIT 
nitrate) or 2 × 225 μg potassium iodide capsules (NIT + I nitrate + iodide) 2 hours prior to 
arriving at the laboratory on day 6 of supplementation.  This was selected to coincide with the 
6peak plasma [NO2-] attained following ingestion of 8.4 mmol NO3- [8].  A 7-10 day washout 
separated the supplementation periods.  Potassium gluconate and potassium iodide capsules 
were provided by NOW Sports Nutrition (NOW Foods, Bloomingdale, IL, USA) and were 
similar in taste, texture and appearance.   NO3--rich beetroot juice was purchased from James 
White Drinks (Beet It; James White Drinks, Ipswich, UK).                
2.3 Measurements
2.3.1 Blood Pressure
After arrival at the laboratory, subjects were required to rest supine for 10 min in an isolated 
room. Thereafter, blood pressure of the brachial artery was measured whilst the subject was 
supine using an automated sphygmomanometer (Dinamap Pro, GE Medical Systems, Tampa, 
USA).  Five measurements were taken and the mean of the measurements 2-5 was used for 
analysis.
2.3.2 Blood and saliva collection
Following blood pressure measurements, venous blood samples were drawn into 6 mL 
lithium-heparin tubes (Sarstedt, Leicester, UK).   Samples were centrifuged at 4,000 rpm and 
4°C for 10 min, within 1-min of collection.  Plasma was subsequently extracted and 
immediately frozen at -80°C for later analysis of [NO3-] and [NO2-].  Unstimulated saliva 
samples (~ 5 mL) were collected into 30 mL universal containers and 1.5 mL aliquots were 
frozen at -80°C for later analysis of [I-], [NO3-] and [NO2-].  
2.4 Data analysis procedures
2.4.1 [I-] determination
After thawing at room temperature, saliva samples were centrifuged at 1600 g for 10 min, 
and the supernatant was removed for subsequent analysis.  1 mL of saliva supernatant, 1 mL 
of deionised water and 40 μL of ionic strength adjustor were added to a 30 mL universal 
container for assessment of salivary [I-].  Salivary [I-] was determined by plotting the mV 
signal derived from an iodide-selective electrode (PerfectION™, Mettler-Toledo AG, 
Switzerland) against a calibration plot of I- standards. All measures were completed at 22°C.  
72.4.2 [NO3-] and [NO2-] determination
All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO 
intermediates prior to [NO2-] and [NO3-] analysis.  Plasma samples were deproteinized using 
zinc sulfate/sodium hydroxide precipitation prior to determination of [NO3-]. Firstly, 500 μL 
of 0.18 N NaOH was added to 100 µL of sample followed by 5 min incubation at room 
temperature.  Subsequently, samples were treated with 300 μL aqueous ZnSO4 (5% w/v) and 
vortexed for 30 s before undergoing an additional 10 min incubation period at room 
temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was 
removed for subsequent analysis.  The [NO3-] of the deproteinized plasma sample was 
determined by its reduction to NO in the presence of 0.8 % (w/v) VCl3 in 1M HCl within an 
air-tight purging vessel.  Plasma samples were introduced to the vessel via 50 uL injections 
into the septum at the top of the vessel.  The spectral emission of electronically excited 
nitrogen dioxide, derived from the reaction of NO with ozone, was detected by a 
thermoelectrically cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase 
chemiluminescence nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK). 
The [NO3-] was determined by plotting signal (mV) area against a calibration plot of sodium 
nitrate standards.  The [NO2-] of the undiluted (non-deproteinized) plasma was determined by 
its reduction to NO in the presence of glacial acetic acid and aqueous NaI (4% w/v) from 
sodium nitrite standards.  100 uL injections were used for plasma [NO2-] determination.  
After thawing at room temperature, saliva samples were centrifuged for 10 min at 14000 rpm 
and the supernatant was removed for subsequent analysis.  The supernatant was diluted 100 
fold with deionized water and [NO3-] and [NO2-] were determined from 50 uL injections 
using the same reagents describe above for the plasma analyses.  
2.4.3 [TSH] and [T4] determination
Plasma thyroid stimulating hormone ([TSH]) and thyroxine ([T4]) concentrations were 
assessed in duplicate using ELISA kits purchased from DRG Diagnostics (DRG Instruments 
GmbH, Germany).
2.5 Statistics
A one-way repeated-measures ANOVA was employed to determine the effects of the 
different dietary interventions (CON control, NIT nitrate and NIT + I nitrate + iodide) on the 
relevant outcome variables.  Where the analysis revealed a significant main effect for 
supplement, Fishers Least Significant Difference tests were employed to determine the origin 
8of such effects.  All data are presented as mean ± SD unless otherwise indicated.  Statistical 
significance was accepted when P<0.05.  
3. RESULTS
The NO3- and I- supplements administered in this study were well tolerated by all subjects 
with no negative side effects reported.  Subjects consumed all doses of the supplements for 
each experimental condition and self-reported that their diet was consistent across all the 
dietary interventions.  
3.1 Salivary [I-] 
Salivary [I-] responses in the CON control, NIT nitrate and NIT + I nitrate + iodide 
conditions are illustrated in Figure 2.  There was a main effect for supplement on salivary [I-] 
(P<0.05), with salivary [I-] being lower in the NIT nitrate condition (384 ± 245 µg·L-1) 
compared to the CON control (487 ± 305 µg·L-1) and NIT + I nitrate + iodide (794 ± 269 
µg·L-1) conditions (P<0.05), and higher than both the NIT nitrate and CON control conditions 
compared to the NIT + I nitrate + iodide condition (P<0.05). 
3.2 Plasma [TSH] and [T4] 
Plasma [TSH] and [T4] responses in the CON control, NIT nitrate and NIT + I nitrate + 
iodide conditions are presented in Table 1.  There were no differences in [TSH] or [T4] 
between the CON control, NIT nitrate and NIT + I nitrate + iodide conditions (P>0.05).     
3.3 Salivary [NO3-] and [NO2-] 
The changes in salivary [NO3-] and [NO2-] in the NIT nitrate and NIT + I nitrate + iodide 
conditions relative to CON control are illustrated in Figure 3.  There were main effects for 
supplement for salivary [NO3-] and [NO2-] (P<0.05).  Salivary [NO3-] and [NO2-] were 
greater in NIT the nitrate (8318 ± 2399 and 2168 ± 1302 µM) and NIT + I nitrate + iodide 
(6630 ± 3516 and 1952 ± 1316 µM) trials compared to CON control (168 ± 177 and 170 ± 
107 µM; P<0.05).  There were no differences between NIT the nitrate (2168 ± 1302 µM) and 
NIT + I nitrate + iodide (1952 ± 1316 µM) trials for salivary [NO2-] (P>0.05), but there was a 
trend (P=0.07) for a higher salivary [NO3-] in NIT the nitrate trial (8318 ± 2399 µM) 
compared to NIT + I the nitrate + iodide trial (6630 ± 3516 µM).   
93.4 Plasma [NO3-] and [NO2-] 
The changes in plasma [NO3-] and [NO2-] in the NIT nitrate and NIT + I nitrate + iodide 
conditions relative to CON control are illustrated in Figure 4.  There were main effects for 
supplement for plasma [NO3-] and [NO2-] (P<0.05).  Plasma [NO3-] and [NO2-] were greater 
in NIT the nitrate (438 ± 117 µM and 404 ± 142 nM) and NIT + I nitrate + iodide (474 ± 127 
µM and 407 ± 145 nM) trials compared to CON control (26 ± 7 µM and 86 ± 22 nM P<0.05).  
Plasma [NO3-] was higher in NIT + I the nitrate + iodide (474 ± 127 µM) trial compared to 
NIT the nitrate trial (438 ± 117 µM; P<0.05), while plasma [NO2-] was not different between 
NIT the nitrate (404 ± 142 nM) and NIT + I nitrate + iodide trials (407 ± 145 nM; P>0.05).  
3.5 Salivary-plasma [NO3-] and [NO2-] ratios
The salivary-plasma [NO3-] ratio was lower in the NIT + I nitrate + iodide trial (14 ± 6 µM) 
compared to NIT nitrate trial (20 ± 6 µM; P<0.05; Figure 5).  The salivary-plasma [NO2-] 
ratio was not different between the NIT + I nitrate + iodide (5184 ± 3481 µM) and NIT 
nitrate conditions (5552 ± 3145 µM; P>0.05; Figure 4).  
 
3.6 Blood pressure responses 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure 
(MAP) responses in the CON control, NIT nitrate and NIT + I nitrate + iodide conditions are 
presented in Table 2.  There were main effects for supplement for SBP, DBP and MAP 
(P<0.05).  SBP and MAP were lower than CON control in both NIT the nitrate and NIT + I 
nitrate + iodide trials (P<0.05), while DBP was only lower than CON control in NIT the 
nitrate trial (P<0.05; Table 2).  There were no differences in any of the blood pressure 
variables between NIT the nitrate and NIT + I nitrate + iodide trials (P>0.05).  The change in 
plasma [NO2-] tended to be negatively correlated with the change in SBP between the CON 
control and NIT nitrate trials (r =-0.65; P=0.06).
4. DISCUSSION
The main original findings from this study were: 1) salivary NO3- uptake was lower after co-
ingesting NO3- and I- compared to NO3- ingested alone (as reflected by a higher plasma [NO3-
] and a lower salivary-plasma [NO3-] ratio in the former compared to the latter); and 2) 
circulating plasma [NO2-] was increased and blood pressure was lowered to a similar extent 
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after ingesting NO3- with and without I- co-ingestion.  Therefore, while increased dietary I- 
has the potential to impede salivary NO3- uptake, in the present study this did not blunt the 
increase in plasma [NO2-] and the lowering of blood pressure after short-term dietary NO3- 
supplementation.  These findings suggest that conforming to global initiatives to increase 
dietary I- intake is unlikely to compromise the lowering of blood pressure after dietary NO3- 
ingestion, at least at the NO3- dose administered in this study.
Salivary [I-] was increased above the un-supplemented control by 63% in the NIT + I nitrate 
+ iodide condition in this study.  Interestingly, ingestion of NO3- alone lowered salivary [I-] to 
79% of that observed in the un-supplemented control condition.  This observation 
complements our previous finding of a lower salivary [SCN-] after NO3-ingestion [30].  
Collectively, these findings substantiate notion that SCN-, I- and NO3- compete for a common 
salivary transporter [27], with recent evidence pointing to sialin as the key transport protein 
for salivary NO3- uptake [49].  Importantly, although salivary [I-] was lower in NIT the nitrate 
compared to the CON control trial, TSH and T4 were not different between the CON control, 
NIT nitrate and NIT + I nitrate + iodide trials.   These findings corroborate a previous study 
which reported no differences in thyroid hormones following short-term NO3- 
supplementation [40].  Therefore, while short-term supplementation with 8 mmol NO3- (a 
dose that could be achieved through ingestion of 200-300 g of NO3--rich vegetables [41-43]) 
can lower salivary [I-], this was not sufficient to perturb thyroid gland function.  However, 
chronic supplementation with large > 8 mmol NO3- doses might have the potential to daily is 
not recommended as physiological effects on blood pressure and exercise capacity are not 
always greater [8, but see 44], and there could be a risk of compromising compromise thyroid 
gland function [44].  In particular, individuals at risk from, or being treated for, 
hypothyroidism are not recommended to consume excessive NO3-.  Further research is 
required to assess the effects of dietary NO3- supplementation on thyroid function to optimise 
supplementation guidelines for different populations. 
The short-term dietary NO3- supplementation regime employed in this study increased 
salivary and plasma [NO3-] and [NO2-], consistent with several previous reports [6,18,33,37, 
38,45].  However, when the same absolute NO3- dose was co-ingested with I-, plasma [NO3-] 
was 8% higher, salivary [NO3-] was 20% lower (P=0.07) and the salivary-plasma [NO3-] ratio 
was 30% lower.  These findings support the notion of an antagonistic effect of I- on salivary 
NO3- uptake, a key rate-limiting step for dietary NO3- metabolism in mammals [26], in line 
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with previous observations [27].  However, despite a lower salivary NO3- uptake, salivary 
[NO2-] was not different between the NIT + I nitrate + iodide and NIT nitrate trials.  This 
observation is similar to our recent study in smokers who, compared to non-smokers, 
exhibited a smaller increase in salivary [NO3-], but a similar increase in salivary [NO2-], after 
ingesting the same NO3- dose [30].  In line with the salivary [NO2-] results, and in spite of the 
potential for increased NO generation in the stomach with NO3- and I- co-ingestion [32,33], 
plasma [NO2-] was not different between the NIT + I nitrate + iodide and NIT nitrate trials.  
Therefore, while salivary NO3- uptake was compromised in NIT + I the nitrate + iodide trial 
compared to NIT the nitrate trial, salivary and plasma [NO2-] were similarly increased in NIT 
the nitrate and NIT + I nitrate + iodide trials.  We cannot, however, exclude the possibility 
that I- ingestion might impact salivary NO3- uptake, and its subsequent metabolism, at lower 
NO3-doses.
Consistent with numerous previous reports [6,8,30,42,43,46], SBP was lowered by 6 mmHg 
in the NIT nitrate trial in this study compared to CON control.  Likewise, a 6 mmHg lowering 
in SBP was observed in the NIT + I nitrate + iodide trial compared to CON control.  In 
keeping with previous reports [8,47], the change in SBP following dietary NO3- 
supplementation tended (P=0.06) to be negatively correlated with the change in plasma [NO2-
].  The association between the increase in circulating plasma [NO2-] and lower SBP after 
NO3- supplementation may be the result of vasodilation evoked from a direct effect of NO2- 
on the vasculature [22,23] and/or NO2- reduction to NO [24].  These changes might be 
mediated by increased plasma [cGMP] [47], or altered renal physiology [48].  Therefore, the 
similar reduction in SBP in the NIT nitrate and NIT + I nitrate + iodide groups is likely to be 
a function of the similar increase in plasma [NO2-] in these groups.  These findings suggest 
that increasing dietary NO3- intake concomitant with increased dietary I- is unlikely to 
compromise the increase in circulating plasma [NO2-] and associated lowering of blood 
pressure.  Taken together our results suggest that consuming a supra-ADI dose of I- perturbed 
dietary NO3- uptake, but this was not a physiologically relevant change as the increase in 
circulating plasma [NO2-] and the lowering of blood pressure were similar after ingesting 
NO3- with or without I- co-ingestion.  However, we acknowledge that potassium intake, 
which has the potential to independently lower blood pressure, particularly in hypertensive 
individuals [49], was higher in the nitrate trial (NO3--rich beetroot juice and 198 mg 
potassium gluconate) compared to the nitrate + iodide trial (NO3--rich beetroot juice and 450 
μg potassium iodide), and this might have impacted on the blood pressure findings in this 
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study.  However, since our subjects were all normotensive, and since there is evidence that 
potassium supplementation is unlikely to measurably impact blood pressure in normotensive 
adults [50-52], the inter-trial differences in potassium intake is unlikely to have confounded 
interpretation of the blood pressure results in this study.   
The impetus for increased population dietary I- intake originated from Switzerland and the 
USA, where salt iodisation was mandated in the 1920s in an attempt to alleviate 
hypothyroidism [34].  These initiatives have proven effective at increasing I- exposure and 
lowering the incidence of hypothyroidism [36].  Consequently, numerous countries have 
imposed salt iodisation programmes or the manufacture of certain food products with iodised 
salt [35,36].  The recommended adequate daily intake (ADI) for I- is 150 μg for adult males 
and females, and 200 μg during pregnancy and lactation [53].  These doses could readily be 
achieved through a diet rich in seafood and dairy products [34], but the I- dose administered 
in this study (450 μg·day-1) exceeded the upper range of average daily I- in the USA where 
iodised salt is mandated [54].  However, despite administering a large I- dose in this study 
(i.e., an I- dose that is not likely to be achieved by most individuals through the diet), the 
increase in plasma [NO2-] and the lowering of blood pressure after NO3- supplementation 
were not different with or without co-ingestion of I-.  Therefore, our results imply that 
conforming to global initiatives to increase dietary I- intake is unlikely to impede the 
lowering of blood pressure after ingesting a NO3- dose equivalent to a few hundred grams of 
NO3--rich vegetables such as spinach, lettuce or rocket [41-43].  However, it is unclear 
whether dietary I- supplementation can interfere with NO3- metabolism and vascular function 
in the absence of dietary NO3- supplementation or at a NO3- dose lower than administered in 
the current study.  Further research is required to address these questions.  
5. CONCLUSION
In conclusion, concurrent I- and NO3- ingestion lowered salivary NO3- uptake, as indicated by 
a higher plasma [NO3-] and a lower salivary-plasma [NO3-] ratio, compared to the same dose 
of  NO3- consumed without I- co-ingestion.  However, despite a lower salivary NO3- uptake 
with I- and NO3- co-ingestion, salivary and plasma [NO2-] were elevated and blood pressure 
was lowered to a similar extent when NO3- was consumed with or without I- co-ingestion.  
These observations are important because they suggest that increasing dietary I-, which is 
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encouraged in several countries worldwide through salt iodisation programmes, does not 
interfere with the lowering of blood pressure after NO3- supplementation, even when a supra-
ADI I- dose is administered.  Therefore, our results suggest that conforming to global 
initiatives to increase dietary I- is unlikely to compromise the ability of a NO3- enriched diet 
to improve blood pressure. 
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Figure 1:  A schematic of the experimental design. 
Figure 2:  Salivary iodide concentration ([I-]) following no dietary supplementation (CON 
control), supplementation with nitrate-rich beetroot juice (NIT nitrate) and co-
supplementation with NIT nitrate and potassium iodide (NIT + I nitrate + iodide).  The filled 
bars represent the group mean ± SEM responses in the CON control, NIT nitrate and NIT + I 
nitrate + iodide conditions.  The solid grey lines represent the individual responses in the 
CON control, NIT nitrate and NIT + I nitrate + iodide conditions.  * indicates significantly 
different from CON control and NIT + I nitrate + iodide. # indicates significantly different 
from CON control and NIT nitrate.  
Figure 3:  Salivary nitrate concentration ([NO3-]) (upper panel) and nitrite concentration 
([NO2-]) (lower panel) following supplementation with nitrate-rich beetroot juice (NIT 
nitrate) and co-supplementation with NIT nitrate and potassium iodide (NIT + I nitrate + 
iodide).  Data are expressed as the change from the control condition without NO3- or I- 
supplementation.   The filled bars represent the group mean ± SEM responses while the solid 
grey lines represent the individual responses in the NIT nitrate and NIT + I nitrate + iodide 
conditions.  There was a trend for a lower salivary [NO3-] in the NIT + I nitrate + iodide trial 
compared to the NIT nitrate trial (P=0.07). 
Figure 4:  Plasma nitrate concentration ([NO3-]) (upper panel) and nitrite concentration 
([NO2-]) (lower panel) following supplementation with nitrate-rich beetroot juice (NIT 
nitrate) and co-supplementation with NIT and potassium iodide (NIT + I).  Data are 
expressed as the change from the control condition without NO3- or I- supplementation.  The 
filled bars represent the group mean ± SEM responses while the solid grey lines represent the 
individual responses in the NIT nitrate and NIT + I nitrate + iodide conditions. * indicates 
significantly different from NIT nitrate.   
Figure 5:  Salivary-plasma nitrate [NO3-] (upper panel) and nitrite [NO2-] (lower panel) ratios 
following supplementation with nitrate-rich beetroot juice (NIT nitrate) and co-
supplementation with NIT nitrate and potassium iodide (NIT + I nitrate + iodide).  The filled 
bars represent the group mean ± SEM responses while the solid grey lines represent the 
individual responses in the NIT nitrate and NIT + I nitrate + iodide conditions. * indicates 
significantly different from NIT nitrate.   
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2ABSTRACT
Uptake of inorganic nitrate (NO3-) into the salivary circulation is a rate-limiting step for 
dietary NO3- metabolism in mammals.  It has been suggested that salivary NO3- uptake occurs 
in competition with inorganic iodide (I-).  Therefore, this study tested the hypothesis that I- 
supplementation would interfere with NO3- metabolism and blunt blood pressure reductions 
after dietary NO3- supplementation.  Nine healthy adults (4 male, mean ± SD, age 20 ± 1 yr) 
reported to the laboratory for initial baseline assessment (control) and following six day 
supplementation periods with 140 ml·day-1 NO3--rich beetroot juice (8.4 mmol NO3-·day-1) 
and 198 mg potassium gluconate·day-1 (nitrate), and 140 ml·day-1 NO3--rich beetroot juice 
and 450 μg potassium iodide·day-1 (nitrate + iodide) in a randomized, cross-over experiment.  
Salivary [I-] was higher in the nitrate + iodide compared to the control and NIT trials 
(P<0.05).  Salivary and plasma [NO3-] and [NO2-] were higher in the nitrate and nitrate + 
iodide trials compared to the control trial (P<0.05).  Plasma [NO3-] was higher (474 ± 127 vs. 
438 ± 117 µM) and the salivary-plasma [NO3-] ratio was lower (14 ± 6 vs. 20 ± 6 µM), 
indicative of a lower salivary NO3- uptake, in the nitrate + iodide trial compared to the nitrate 
trial (P<0.05).  Plasma and salivary [NO2-] were not different between the nitrate and nitrate 
+ iodide trials (P>0.05).  Systolic blood pressure was lower than control (112 ± 13 mmHg) in 
the nitrate (106 ± 13 mmHg) and nitrate + iodide (106 ± 11 mmHg) trials (P<0.05), with no 
differences between the nitrate and nitrate + iodide trials (P>0.05).  In conclusion, co-
ingesting NO3- and I- perturbed salivary NO3- uptake, but the increase in salivary and plasma 
[NO2-] and the lowering of blood pressure were similar, compared to NO3- ingestion alone.  
Therefore, increased dietary I- intake, which is recommended in several countries worldwide 
as an initiative to offset hypothyroidism, does not appear to compromise the blood pressure 
reduction afforded by increased dietary NO3- intake.    
Key Words: Entero-salivary circulation; nitrite; nitric oxide; vascular health; nutrition 
31. INTRODUCTION
The gaseous molecule, nitric oxide (NO), regulates an array of physiological processes, but is 
perhaps best known for its vasodilatory and cardioprotective properties [1,2].  It has been 
demonstrated that NO can be generated through the O2-independent reduction of nitrite (NO2-
) to complement O2-dependent NO generation through the NO synthases [3-5].  The 
circulating plasma [NO2-] can be increased through dietary supplementation with inorganic 
nitrate (NO3-) and is associated with a reduction in blood pressure and arterial stiffness [6-8], 
important predictors of future adverse cardiovascular events [9,10].  In addition, NO3- 
supplementation can improve vascular function in healthy older adults [11] and some clinical 
populations including patients with peripheral artery disease [12] and heart failure [13].  
Increasing dietary NO3- intake, therefore, appears to confer cardioprotective effects and might 
hold promise as a nutritional intervention to lower the societal and economic burden of 
cardiovascular diseases [14]. 
Approximately 25% of NO3- consumed through the diet is actively taken up and concentrated 
by the salivary glands [15].  NO3- is then transported in saliva to the mouth for second-pass 
metabolism via the so-called entero-salivary circulation [15-19].  Upon arrival of NO3--rich 
saliva at the oral cavity, microflora on the tongue reduce NO3- to NO2- [15-19].  After 
swallowing this NO2--rich saliva, NO2- is chemically reduced to NO and other reactive 
nitrogen intermediates in the acidic environment of the stomach [20,21], but it is well 
documented that the circulating plasma [NO2-] is also increased after increased NO3- intake 
[6-8,18].  This circulating plasma NO2- can then impact vascular function either through 
direct NO2- action [22,23] or through its subsequent reduction to NO via numerous NO2- 
reductases [24].  While mammalian tissue is capable of reducing NO3- to NO2- [25], the rate 
limiting steps for NO3- reduction in mammals are NO3- transport into the entero-salivary 
circulation and NO3- reduction to NO2- by the oral microflora [26].  Importantly, the anions 
perchlorate (CIO4-), thiocyanate (SCN-), iodide (I-) and NO3- share a common transporter for 
uptake into the salivary glands, with the order of affinity for salivary uptake being CIO4- > 
SCN- > I- > NO3- [27].  Although CIO4- has the highest affinity for salivary uptake of the 
aforementioned anions [27], environmental exposure to CIO4- is limited [28,29].  
Consequently, the competition between SCN-, I- and NO3- is more likely to be pertinent for 
4NO3- transfer into the entero-salivary circulation [28,29] and, subsequently, the stepwise 
reduction of NO3- to NO2- and then NO. 
It has recently been reported that cigarette smoking [30], which increased salivary and plasma 
[SCN-], perturbed aspects of dietary NO3- metabolism, and thwarted the lowering of blood 
pressure, after dietary NO3- supplementation.  There is evidence to suggest that compared to 
nitrate iodide is ~ 8 times more effective at competitively inhibiting the anion transporter in 
the human thyroid gland [31].  Although I- has previously been suggested to interfere with 
salivary NO3- uptake [27], the relative potency of I- to inhibit salivary NO3- uptake has yet to 
be determined.  As such, it is unclear whether increasing the circulating [I-] via I- 
supplementation can compromise salivary NO3- uptake after NO3- ingestion.  However, it is 
also possible that any potential perturbation to salivary NO3- uptake after NO3- and I- co-
ingestion might be offset by a compensatory increase in NO generation in the stomach.  
Indeed, nitrous acid (HNO2), which is formed from the protonation of ingested salivary NO2- 
in the stomach [32], can react with I- to form NO at an acidic pH [33].  Accordingly, further 
research is required to assess the extent to which dietary I- enrichment impacts dietary NO3- 
metabolism and associated vascular health benefits after dietary NO3- supplementation.  This 
is important because I- is present in numerous food sources, with seafood and dairy products, 
particularly seaweed, white fish, yogurt and milk, being abundant in I- [34].  Moreover, in 
excess of 100 countries fortify their salt with I-, or mandate the use of iodised salt for the 
production of products such as bread, in an effort to alleviate the prevalence of 
hypothyroidism [35,36].  These government initiatives have been successful at increasing I- 
exposure [36], but it is unclear if this might be to the detriment of dietary NO3- metabolism.     
The purpose of this study was to examine the effect of co-supplementation with NO3- and I-, 
compared to NO3- supplementation alone, on dietary NO3- metabolism and blood pressure.  
We hypothesised that NO3- supplementation would increase salivary and plasma [NO3-] and 
[NO2-] and lower blood pressure, but that concurrent NO3- and I- supplementation would 
attenuate: 1) salivary NO3- uptake, 2) the increase in circulating plasma [NO2-] and 3) the 
lowering of blood pressure compared to NO3- supplementation alone.     
52. METHODS
2.1 Subject characteristics
We recruited nine healthy non-smoking adults (4 males, mean ± SD, age 20 ± 1 yr, body 
mass 71 ± 16 kg, height 1.72 ± 0.11 m) to participate in this study.  All procedures employed 
in this study were approved by the Institutional Research Ethics Committee and subjects gave 
their written informed consent to participate after the experimental procedures, associated 
risks, and potential benefits of participation had been explained.  Subjects were instructed to 
arrive at each laboratory testing session in a rested and fully hydrated state, at least 3 h 
postprandial.  Since the reduction of NO3- to NO2- in the oral cavity is abolished by 
antibacterial mouthwash [37,38], subjects were required to refrain from mouthwash use for 
the duration of the study.  Each subject was given a list of NO3--rich and SCN--rich foods and 
asked to avoid consumption of these foods for the duration of the study, and to abstain from 
caffeine and alcohol ingestion 6 and 24 h before each test, respectively.  Subjects were 
instructed to maintain their habitual exercise pattern for the duration of the study.   All tests 
were performed at the same time of day (± 2 hours).   
2.2 Supplementation Procedures
All subjects were required to report to the laboratory on three occasions over a 3-4 week 
period.  Subjects did not undergo dietary supplementation prior to their first visit to the 
laboratory (the control condition).  Subjects were asked to record their food and beverage 
consumption on the day of the control test and for the 2 days preceding this test and to 
replicate this prior to the subsequent trials.  After completing the control trial, subjects were 
randomly assigned to receive six days of supplementation with 2 × 70 ml NO3--rich beetroot 
juice (8.4 mmol NO3-) and 2 × 99 mg potassium gluconate placebo capsules (nitrate), or 2 × 
70 ml NO3--rich beetroot juice and 2 × 225 μg potassium iodide capsules (nitrate + iodide), 
per day as part of a double-blind, cross-over experimental design (Figure 1).  Subjects 
consumed 1 × 70 ml NO3--rich beetroot juice and 1 × 99 mg potassium gluconate placebo 
capsule (nitrate) or 1 × 225 μg potassium iodide capsule (nitrate + iodide) in the morning and 
evening on days 1-5 of supplementation and 2 × 70 ml NO3--rich beetroot juice with 2 × 99 
mg potassium gluconate placebo capsules (nitrate) or 2 × 225 μg potassium iodide capsules 
(nitrate + iodide) 2 hours prior to arriving at the laboratory on day 6 of supplementation.  
This was selected to coincide with the peak plasma [NO2-] attained following ingestion of 8.4 
6mmol NO3- [8].  A 7-10 day washout separated the supplementation periods.  Potassium 
gluconate and potassium iodide capsules were provided by NOW Sports Nutrition (NOW 
Foods, Bloomingdale, IL, USA) and were similar in taste, texture and appearance.   NO3--rich 
beetroot juice was purchased from James White Drinks (Beet It; James White Drinks, 
Ipswich, UK).                
2.3 Measurements
2.3.1 Blood Pressure
After arrival at the laboratory, subjects were required to rest supine for 10 min in an isolated 
room. Thereafter, blood pressure of the brachial artery was measured whilst the subject was 
supine using an automated sphygmomanometer (Dinamap Pro, GE Medical Systems, Tampa, 
USA).  Five measurements were taken and the mean of the measurements 2-5 was used for 
analysis.
2.3.2 Blood and saliva collection
Following blood pressure measurements, venous blood samples were drawn into 6 mL 
lithium-heparin tubes (Sarstedt, Leicester, UK).   Samples were centrifuged at 4,000 rpm and 
4°C for 10 min, within 1-min of collection.  Plasma was subsequently extracted and 
immediately frozen at -80°C for later analysis of [NO3-] and [NO2-].  Unstimulated saliva 
samples (~ 5 mL) were collected into 30 mL universal containers and 1.5 mL aliquots were 
frozen at -80°C for later analysis of [I-], [NO3-] and [NO2-].  
2.4 Data analysis procedures
2.4.1 [I-] determination
After thawing at room temperature, saliva samples were centrifuged at 1600 g for 10 min, 
and the supernatant was removed for subsequent analysis.  1 mL of saliva supernatant, 1 mL 
of deionised water and 40 μL of ionic strength adjustor were added to a 30 mL universal 
container for assessment of salivary [I-].  Salivary [I-] was determined by plotting the mV 
signal derived from an iodide-selective electrode (PerfectION™, Mettler-Toledo AG, 
Switzerland) against a calibration plot of I- standards. All measures were completed at 22°C.  
72.4.2 [NO3-] and [NO2-] determination
All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO 
intermediates prior to [NO2-] and [NO3-] analysis.  Plasma samples were deproteinized using 
zinc sulfate/sodium hydroxide precipitation prior to determination of [NO3-]. Firstly, 500 μL 
of 0.18 N NaOH was added to 100 µL of sample followed by 5 min incubation at room 
temperature.  Subsequently, samples were treated with 300 μL aqueous ZnSO4 (5% w/v) and 
vortexed for 30 s before undergoing an additional 10 min incubation period at room 
temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was 
removed for subsequent analysis.  The [NO3-] of the deproteinized plasma sample was 
determined by its reduction to NO in the presence of 0.8 % (w/v) VCl3 in 1M HCl within an 
air-tight purging vessel.  Plasma samples were introduced to the vessel via 50 uL injections 
into the septum at the top of the vessel.  The spectral emission of electronically excited 
nitrogen dioxide, derived from the reaction of NO with ozone, was detected by a 
thermoelectrically cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase 
chemiluminescence nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK). 
The [NO3-] was determined by plotting signal (mV) area against a calibration plot of sodium 
nitrate standards.  The [NO2-] of the undiluted (non-deproteinized) plasma was determined by 
its reduction to NO in the presence of glacial acetic acid and aqueous NaI (4% w/v) from 
sodium nitrite standards.  100 uL injections were used for plasma [NO2-] determination.  
After thawing at room temperature, saliva samples were centrifuged for 10 min at 14000 rpm 
and the supernatant was removed for subsequent analysis.  The supernatant was diluted 100 
fold with deionized water and [NO3-] and [NO2-] were determined from 50 uL injections 
using the same reagents describe above for the plasma analyses.  
2.4.3 [TSH] and [T4] determination
Plasma thyroid stimulating hormone ([TSH]) and thyroxine ([T4]) concentrations were 
assessed in duplicate using ELISA kits purchased from DRG Diagnostics (DRG Instruments 
GmbH, Germany).
2.5 Statistics
A one-way repeated-measures ANOVA was employed to determine the effects of the 
different dietary interventions (control, nitrate and nitrate + iodide) on the relevant outcome 
variables.  Where the analysis revealed a significant main effect for supplement, Fishers 
Least Significant Difference tests were employed to determine the origin of such effects.  All 
8data are presented as mean ± SD unless otherwise indicated.  Statistical significance was 
accepted when P<0.05.  
3. RESULTS
The NO3- and I- supplements administered in this study were well tolerated by all subjects 
with no negative side effects reported.  Subjects consumed all doses of the supplements for 
each experimental condition and self-reported that their diet was consistent across all the 
dietary interventions.  
3.1 Salivary [I-] 
Salivary [I-] responses in the control, nitrate and nitrate + iodide conditions are illustrated in 
Figure 2.  There was a main effect for supplement on salivary [I-] (P<0.05), with salivary [I-] 
being lower in the nitrate condition (384 ± 245 µg·L-1) compared to the control (487 ± 305 
µg·L-1) and nitrate + iodide (794 ± 269 µg·L-1) conditions (P<0.05), and higher than both the 
nitrate and control conditions compared to the nitrate + iodide condition (P<0.05). 
3.2 Plasma [TSH] and [T4] 
Plasma [TSH] and [T4] responses in the control, nitrate and nitrate + iodide conditions are 
presented in Table 1.  There were no differences in [TSH] or [T4] between the control, nitrate 
and nitrate + iodide conditions (P>0.05).     
3.3 Salivary [NO3-] and [NO2-] 
The changes in salivary [NO3-] and [NO2-] in the nitrate and nitrate + iodide conditions 
relative to control are illustrated in Figure 3.  There were main effects for supplement for 
salivary [NO3-] and [NO2-] (P<0.05).  Salivary [NO3-] and [NO2-] were greater in the nitrate 
(8318 ± 2399 and 2168 ± 1302 µM) and nitrate + iodide (6630 ± 3516 and 1952 ± 1316 µM) 
trials compared to control (168 ± 177 and 170 ± 107 µM; P<0.05).  There were no 
differences between the nitrate and nitrate + iodide trials for salivary [NO2-] (P>0.05), but 
there was a trend (P=0.07) for a higher salivary [NO3-] in the nitrate trial compared to the 
nitrate + iodide trial.   
93.4 Plasma [NO3-] and [NO2-] 
The changes in plasma [NO3-] and [NO2-] in the nitrate and nitrate + iodide conditions 
relative to control are illustrated in Figure 4.  There were main effects for supplement for 
plasma [NO3-] and [NO2-] (P<0.05).  Plasma [NO3-] and [NO2-] were greater in the nitrate 
(438 ± 117 µM and 404 ± 142 nM) and nitrate + iodide (474 ± 127 µM and 407 ± 145 nM) 
trials compared to control (26 ± 7 µM and 86 ± 22 nM P<0.05).  Plasma [NO3-] was higher in 
the nitrate + iodide trial compared to the nitrate trial (P<0.05), while plasma [NO2-] was not 
different between the nitrate and nitrate + iodide trials (P>0.05).  
3.5 Salivary-plasma [NO3-] and [NO2-] ratios
The salivary-plasma [NO3-] ratio was lower in the nitrate + iodide trial (14 ± 6 µM) compared 
to nitrate trial (20 ± 6 µM; P<0.05; Figure 5).  The salivary-plasma [NO2-] ratio was not 
different between the nitrate + iodide (5184 ± 3481 µM) and nitrate conditions (5552 ± 3145 
µM; P>0.05; Figure 4).  
 
3.6 Blood pressure responses 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure 
(MAP) responses in the control, nitrate and nitrate + iodide conditions are presented in Table 
2.  There were main effects for supplement for SBP, DBP and MAP (P<0.05).  SBP and 
MAP were lower than control in both the nitrate and nitrate + iodide trials (P<0.05), while 
DBP was only lower than control in the nitrate trial (P<0.05; Table 2).  There were no 
differences in any of the blood pressure variables between the nitrate and nitrate + iodide 
trials (P>0.05).  The change in plasma [NO2-] tended to be negatively correlated with the 
change in SBP between the control and nitrate trials (r =-0.65; P=0.06).
4. DISCUSSION
The main original findings from this study were: 1) salivary NO3- uptake was lower after co-
ingesting NO3- and I- compared to NO3- ingested alone (as reflected by a higher plasma [NO3-
] and a lower salivary-plasma [NO3-] ratio in the former compared to the latter); and 2) 
circulating plasma [NO2-] was increased and blood pressure was lowered to a similar extent 
after ingesting NO3- with and without I- co-ingestion.  Therefore, while increased dietary I- 
has the potential to impede salivary NO3- uptake, in the present study this did not blunt the 
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increase in plasma [NO2-] and the lowering of blood pressure after short-term dietary NO3- 
supplementation.  These findings suggest that conforming to global initiatives to increase 
dietary I- intake is unlikely to compromise the lowering of blood pressure after dietary NO3- 
ingestion, at least at the NO3- dose administered in this study.
Salivary [I-] was increased above the un-supplemented control by 63% in the nitrate + iodide 
condition in this study.  Interestingly, ingestion of NO3- alone lowered salivary [I-] to 79% of 
that observed in the un-supplemented control condition.  This observation complements our 
previous finding of a lower salivary [SCN-] after NO3-ingestion [30].  Collectively, these 
findings substantiate notion that SCN-, I- and NO3- compete for a common salivary 
transporter [27], with recent evidence pointing to sialin as the key transport protein for 
salivary NO3- uptake [49].  Importantly, although salivary [I-] was lower in the nitrate 
compared to the control trial, TSH and T4 were not different between the control, nitrate and 
nitrate + iodide trials.   These findings corroborate a previous study which reported no 
differences in thyroid hormones following short-term NO3- supplementation [40].  Therefore, 
while short-term supplementation with 8 mmol NO3- (a dose that could be achieved through 
ingestion of 200-300 g of NO3--rich vegetables [41-43]) can lower salivary [I-], this was not 
sufficient to perturb thyroid gland function.  However, chronic supplementation with large 
NO3- doses might have the potential to compromise thyroid gland function [44].  Further 
research is required to assess the effects of dietary NO3- supplementation on thyroid function 
to optimise supplementation guidelines for different populations. 
The short-term dietary NO3- supplementation regime employed in this study increased 
salivary and plasma [NO3-] and [NO2-], consistent with several previous reports [6,18,33,37, 
38,45].  However, when the same absolute NO3- dose was co-ingested with I-, plasma [NO3-] 
was 8% higher, salivary [NO3-] was 20% lower (P=0.07) and the salivary-plasma [NO3-] ratio 
was 30% lower.  These findings support the notion of an antagonistic effect of I- on salivary 
NO3- uptake, a key rate-limiting step for dietary NO3- metabolism in mammals [26], in line 
with previous observations [27].  However, despite a lower salivary NO3- uptake, salivary 
[NO2-] was not different between the nitrate + iodide and nitrate trials.  This observation is 
similar to our recent study in smokers who, compared to non-smokers, exhibited a smaller 
increase in salivary [NO3-], but a similar increase in salivary [NO2-], after ingesting the same 
NO3- dose [30].  In line with the salivary [NO2-] results, and in spite of the potential for 
increased NO generation in the stomach with NO3- and I- co-ingestion [32,33], plasma [NO2-] 
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was not different between the nitrate + iodide and nitrate trials.  Therefore, while salivary 
NO3- uptake was compromised in the nitrate + iodide trial compared to the nitrate trial, 
salivary and plasma [NO2-] were similarly increased in the nitrate and nitrate + iodide trials.  
Consistent with numerous previous reports [6,8,30,42,43,46], SBP was lowered by 6 mmHg 
in the nitrate trial in this study compared to control.  Likewise, a 6 mmHg lowering in SBP 
was observed in the nitrate + iodide trial compared to control.  In keeping with previous 
reports [8,47], the change in SBP following dietary NO3- supplementation tended (P=0.06) to 
be negatively correlated with the change in plasma [NO2-].  The association between the 
increase in circulating plasma [NO2-] and lower SBP after NO3- supplementation may be the 
result of vasodilation evoked from a direct effect of NO2- on the vasculature [22,23] and/or 
NO2- reduction to NO [24].  These changes might be mediated by increased plasma [cGMP] 
[47], or altered renal physiology [48].  Therefore, the similar reduction in SBP in the nitrate 
and nitrate + iodide groups is likely to be a function of the similar increase in plasma [NO2-] 
in these groups.  Taken together our results suggest that consuming a supra-ADI dose of I- 
perturbed dietary NO3- uptake, but this was not a physiologically relevant change as the 
increase in circulating plasma [NO2-] and the lowering of blood pressure were similar after 
ingesting NO3- with or without I- co-ingestion.  However, we acknowledge that potassium 
intake, which has the potential to independently lower blood pressure, particularly in 
hypertensive individuals [49], was higher in the nitrate trial (NO3--rich beetroot juice and 198 
mg potassium gluconate) compared to the nitrate + iodide trial (NO3--rich beetroot juice and 
450 μg potassium iodide), and this might have impacted on the blood pressure findings in this 
study.  However, since our subjects were all normotensive, and since there is evidence that 
potassium supplementation is unlikely to measurably impact blood pressure in normotensive 
adults [50-52], the inter-trial differences in potassium intake is unlikely to have confounded 
interpretation of the blood pressure results in this study.   
The impetus for increased population dietary I- intake originated from Switzerland and the 
USA, where salt iodisation was mandated in the 1920s in an attempt to alleviate 
hypothyroidism [34].  These initiatives have proven effective at increasing I- exposure and 
lowering the incidence of hypothyroidism [36].  Consequently, numerous countries have 
imposed salt iodisation programmes or the manufacture of certain food products with iodised 
salt [35,36].  The recommended adequate daily intake (ADI) for I- is 150 μg for adult males 
and females, and 200 μg during pregnancy and lactation [53].  These doses could readily be 
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achieved through a diet rich in seafood and dairy products [34], but the I- dose administered 
in this study (450 μg·day-1) exceeded the upper range of average daily I- in the USA where 
iodised salt is mandated [54].  However, despite administering a large I- dose in this study 
(i.e., an I- dose that is not likely to be achieved by most individuals through the diet), the 
increase in plasma [NO2-] and the lowering of blood pressure after NO3- supplementation 
were not different with or without co-ingestion of I-.  Therefore, our results imply that 
conforming to global initiatives to increase dietary I- intake is unlikely to impede the 
lowering of blood pressure after ingesting a NO3- dose equivalent to a few hundred grams of 
NO3--rich vegetables such as spinach, lettuce or rocket [41-43].  However, it is unclear 
whether dietary I- supplementation can interfere with NO3- metabolism and vascular function 
in the absence of dietary NO3- supplementation or at a NO3- dose lower than administered in 
the current study.  Further research is required to address these questions.  
5. CONCLUSION
In conclusion, concurrent I- and NO3- ingestion lowered salivary NO3- uptake, as indicated by 
a higher plasma [NO3-] and a lower salivary-plasma [NO3-] ratio, compared to the same dose 
of  NO3- consumed without I- co-ingestion.  However, despite a lower salivary NO3- uptake 
with I- and NO3- co-ingestion, salivary and plasma [NO2-] were elevated and blood pressure 
was lowered to a similar extent when NO3- was consumed with or without I- co-ingestion.  
These observations are important because they suggest that increasing dietary I-, which is 
encouraged in several countries worldwide through salt iodisation programmes, does not 
interfere with the lowering of blood pressure after NO3- supplementation, even when a supra-
ADI I- dose is administered.  Therefore, our results suggest that conforming to global 
initiatives to increase dietary I- is unlikely to compromise the ability of a NO3- enriched diet 
to improve blood pressure. 
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Figure Legends
Figure 1:  A schematic of the experimental design. 
Figure 2:  Salivary iodide concentration ([I-]) following no dietary supplementation (control), 
supplementation with nitrate-rich beetroot juice (nitrate) and co-supplementation with nitrate 
and potassium iodide (nitrate + iodide).  The filled bars represent the group mean ± SEM 
responses in the control, nitrate and nitrate + iodide conditions.  The solid grey lines represent 
the individual responses in the control, nitrate and nitrate + iodide conditions.  * indicates 
significantly different from control and nitrate + iodide. # indicates significantly different 
from control and nitrate.  
Figure 3:  Salivary nitrate concentration ([NO3-]) (upper panel) and nitrite concentration 
([NO2-]) (lower panel) following supplementation with nitrate-rich beetroot juice (nitrate) and 
co-supplementation with nitrate and potassium iodide (nitrate + iodide).  Data are expressed 
as the change from the control condition without NO3- or I- supplementation.   The filled bars 
represent the group mean ± SEM responses while the solid grey lines represent the individual 
responses in the nitrate and nitrate + iodide conditions.  There was a trend for a lower salivary 
[NO3-] in the nitrate + iodide trial compared to the nitrate trial (P=0.07). 
Figure 4:  Plasma nitrate concentration ([NO3-]) (upper panel) and nitrite concentration 
([NO2-]) (lower panel) following supplementation with nitrate-rich beetroot juice (nitrate) and 
co-supplementation with NIT and potassium iodide (NIT + I).  Data are expressed as the 
change from the control condition without NO3- or I- supplementation.  The filled bars 
represent the group mean ± SEM responses while the solid grey lines represent the individual 
responses in the nitrate and nitrate + iodide conditions. * indicates significantly different 
from nitrate.   
Figure 5:  Salivary-plasma nitrate [NO3-] (upper panel) and nitrite [NO2-] (lower panel) ratios 
following supplementation with nitrate-rich beetroot juice (nitrate) and co-supplementation 
with nitrate and potassium iodide (nitrate + iodide).  The filled bars represent the group mean 
± SEM responses while the solid grey lines represent the individual responses in the nitrate 
and nitrate + iodide conditions. * indicates significantly different from nitrate.   





Table 1. Plasma thyroid stimulating hormone ([TSH]) and thyroxine ([T4]) 
concentrations following no supplementation (CON), nitrate-rich beetroot juice 
supplementation (NIT) and co-supplementation with nitrate-rich beetroot juice 
supplementation and potassium iodide (NIT + I).
CON NIT NIT + I
Plasma [TSH] (mIU/L) 1.2 ± 0.6 1.1 ± 0.6 1.5 ± 0.6
Plasma [T4] (μg/dl) 4.2 ± 0.7 3.8 ± 0.4 3.8 ± 0.9
Values are presented as the mean ± SD. 
Table 2. Resting supine blood pressure measures following no supplementation (CON), 
nitrate-rich beetroot juice supplementation (NIT) and co-supplementation with nitrate-
rich beetroot juice supplementation and potassium iodide (NIT + I).
CON NIT NIT + I
Systolic blood pressure (mmHg) 112 ± 13 106 ± 13* 106 ± 11*
Diastolic blood pressure (mmHg) 59 ± 6 56 ± 4* 57 ± 5
Mean arterial pressure (mmHg) 80 ± 8 75 ± 5* 76 ± 7*
Values are presented as the mean ± SD. * = significantly different from CON (P<0.05). 
HIGHLIGHTS
- Inorganic iodide interfered with salivary nitrate uptake
- The change in plasma [nitrite] was not adversely impacted by iodide supplementation
- Nitrate supplementation lowered blood pressure with and without  iodide co-ingestion
- Iodide supplementation did not compromise the hypotensive effects of nitrate 
supplementation 
